FF
Therapeutic Areas
Geron Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Imetelstat (Rytelo™) | Transfusion-Dependent Anemia in Lower-Risk Myelodysplastic Syndromes (MDS) | Approved |
| Imetelstat | JAK Inhibitor Relapsed/Refractory Myelofibrosis (MF) | Phase 3 |
| Imetelstat + Ruxolitinib | Frontline Myelofibrosis (MF) | Phase 1 |
| Imetelstat + Azacitidine ± Venetoclax | Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | Phase 1 |
Leadership Team at Geron
JA
John A. Scarlett, M.D.
Chief Executive Officer and Chairman
AJ
Andrew J. Grethlein, Ph.D.
Executive Vice President and Chief Operating Officer
MR
Michelle Robertson
Executive Vice President and Chief Financial Officer
AK
Anil Kapur
Executive Vice President, Corporate Strategy and Chief Commercial Officer